Metabolomics & Systems Biology

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Mishra received his B. S (Honors) and M.S degrees from Patna University ( then nicknamed as Oxford of the East) in India and Ph. D Degree from McMaster University. He received his post –doctoral training with the late Nobel Laureate Professor E. L. Tatum at the Rockefeller University. He was a Fellow for Medical Research of the Jane Coffin Child Fund of the Yale University at the Rockefeller University for two years and then Research Associate with Professor Tatum where he initiated his work in what is now called as Proteomics and Matabolomics.

Narendra Yadav Demonstrated success in biotechnology, including two once-in-a-lifetime breakthroughs: 1) Discovered omega 6 desaturase gene that led to the biotech soybean oil Plenish® benefitting farmers (anticipated to be the 4th largest U.S. row crop by 2023), the food industry, and consumers with its zero trans fat oil (“In a Bean, a Boon to Biotech”, New York Times, Nov 15, 2013).2) Engineered yeast into the richest source of omega-3 fatty acids, described by Nature Biotechnology as a ‘metabolic-engineering tour de force’. Its use in VerlassoTM salmon replaced 75% of the wild-caught fish needed in aquaculture to earn the distinction of “better alternative” by Seafood Watch. Inventor on 63 granted patents.  Author on 23 peer-reviewed papers in high impact journals.  Successful metabolic engineering of one plant and two microbes from start to finish and all worked!  Genetically engineered both central and secondary metabolic pathways in plants and microbes.  Genome editing in plants and microbes as well as in their organelles (mitochondria and chloroplasts).  Demonstrated expertise in bioinformatics, gene discovery, cutting edge DNA assembly.  high throughput, automated microbe engineering using Benchling platform and robots, such as Mantis, Bravo, Guava, Tecan, and Fragment Analyzer.

Dr. Bryan earned his undergraduate Bachelor of Science degree in Biochemistry from the University of Texas at Austin and his doctoral degree from Louisiana State University School of Medicine in Shreveport where he was the recipient of the Dean’s Award for Excellence in Research. He pursued his post-doctoral training as a Kirschstein Fellow at Boston University School of Medicine in the Whitaker Cardiovascular Institute. After a two year post-doctoral fellowship, in 2006 Dr. Bryan was recruited to join faculty at the University of Texas Health Science Center at Houston by Ferid Murad, M.D., Ph.D., 1998 Nobel Laureate in Medicine or Physiology. During his tenure as faculty and independent investigator at UT, his research focused on drug discovery through screening natural product libraries for active compounds. His nine years at UT led to several discoveries which have resulted in eight issued US and international patents and nine pending worldwide. Specifically, Dr. Bryan was the first to describe nitrite and nitrate as indispensable nutrients required for optimal cardiovascular health. He was the first to demonstrate and discover an endocrine function of nitric oxide via the formation of S-nitrosoglutathione and inorganic nitrite. Through the drug discovery program in natural product chemistry, Dr. Bryan discovered unique compositions of matter than can be used to safely and effectively generate and restore nitric oxide in humans. This technology is now validated in six published clinical trials and Dr. Bryan has 9 issued US and International patents. He is also a successful entrepreneur who has successfully commercialized his nitric oxide technology through a UT portfolio company, named to the Inc 5000 fastest growing companies in the US for the past 3 years straight. Dr. Bryan has been involved in nitric oxide research for the past 16 years and has made many seminal discoveries in the field. These discoveries and findings have transformed the development of safe and effective functional bioactive natural products in the treatment and prevention of human disease and may provide the basis for new preventive or therapeutic strategies in many chronic diseases. Dr. Bryan has published a number of highly cited papers and authored or edited 5 books. He is an international leader in molecular medicine and nitric oxide biochemistry.

Gerald C. Hsu received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

Boris Zaslavsky graduated in Analytical Chemistry from the Moscow State University. He holds a PhD and a DSc (USSR Academy of Sciences), was a scientist at USSR Academy of Sciences (1971-1991), Visiting Fellow at Cornell University Medical School (NYC, 1991-1992), and KV Pharmaceuticals (1993-1994), Argonne National Laboratory (1994-1995). He is the founder of Analiza, Inc. (1996-present) and Cleveland Diagnostics (2014-present), where serves as a Chief Scientific Officer. He published 1 monograph, over 120 scientific papers, and 7 patents. His research interests are development of analytical applications of aqueous two-phase partitioning, new clinical tests for early cancer detection and other applications, role of water in biology, and protein-water interactions.

Xuanxian Peng is a Professor, School of Life Sciences, Sun Yat-Sen University, China. He received his Ph.D. from Xiamen University, China and studied at McGill University, Canada as a postdoctoral fellow. Professor Peng was the first Dean of School of Life Sciences, Xiamen University, China from 1999 to 2003. He was a member of the fifth Chinese Education Ministry for Sciences and Technology and vice chairmen of Chinese Society for Marine Biochemistry and Molecular Biology. His research focuses on functional metabolomics for antibiotic resistance, which have recently been published in Cell Metabolism and PNAS

Dr Ivan Minic, student of Academic Doctoral studies, Dental science, department of Oral medicine and Parodontology, Medical faculty, University of Nis, Serbia. I participated in several international congresses, the author of more than 25 scientific papers, a member of the editorial board of over 30 journals and reviews over 15 journals.

Petra Perner is the founder and director of the Institute of Computer Vision and Applied Computer Sciences in Leipzig, Germany. Under her leadership the institute developed to one of the leading institutes in basic and applied research in computer vision, data mining, machine learning, case-based reasoning and image databases. She received a diploma degree in electrical engineering in 1981 and a PhD degree in computer science in 1985. In 1989 she finished her habilitation entitled “A Methodology for the Development of Knowledge-Based Image-Interpretation Systems”. Under her guidance highly qualified national and international personnel got trained in the above mentioned high-technology fields through research projects and education programs. The tutorial on Data Mining (www.data-mining-tutorial.de) is a recognized tutorial among the domain experts and is especially designed for training industrial people on hot topics in data mining. She gave courses on Data Mining and Image Interpretation at different universities in various countries. She has been the project leader and principal investigator of various national and international research projects for which she received several research awards. Her projects are marked by the fact that they tie together high-class research with the aspect of the economic application. She is frequently invited as a guest professor for knowledge-based image inspection systems by several national and international institutes and companies. She supervised the foundation of two high-technology companies named ibai-solutions (www.ibai-solutions.de) and ImageInterpret GmbH (www.imageinterpret.de) whose teams received 4 distinct business prices for transferring image-interpretation and data-mining methods to industry. She was the principal founder and chairwoman of the Technical Committee “Machine Learning and Data Mining”. She is the chairwoman of three distinct conferences in Machine Learning, Data Mining and High-Content Analysis of Signals and Images called MLDM (www.mldm.de), ICDM (www.data-mining.forum.de) and MDA (www.mda-signals.de). Presently she is working on various medical, chemical and biomedical applications, information management applications, technical diagnosis and e-commerce applications. Most of the developments are protected by legal patent rights and can be licenced to qualified industries. She has published numerous scientific publications and patents and is frequently requested as pleanary speaker in distinct research fields as well as across disciplinces. Her vision is to build intelligent flexible and robust data-interpreting systems that are inspired by the human case-based reasoning process.

Prof. Xia is the Dean of the School of Public Health, Nanjing Medical University, Vice Director of Center for Global Health and the PI of State Key Laboratory of Reproductive Medicine and Key Laboratory of Modern Toxicology of the Ministry of Education. His current research interests are Systems Biology and Environmental Health. He has been using high-throughput techniques to profile human environmental exposure and biological responses to exogenous chemicals. Prof. Xia has presided over more than ten national and ministerial projects, including the State Key Program of National Natural Science Foundation of China and the National Outstanding Youth Science Foundation. He has been the Committee Member of several domestic and international academic organizations. Prof. Xia has published over 110 peer-reviewed articles, and got 7 national invention patents. He also serves as the editor and reviewer of more than 20 international journals.

Hui Li is a Professor, School of Life Sciences, Sun Yat-Sen University, China. She received her Ph.D. from Sichuan University, China and studied at Sun Yat-sen University,China as a postdoctoral fellow. Her research focuses on functional metabolomics for antibiotic resistance, which have recently been published in Cell Metabolism and PNAS

Bo Peng has his expertise in metabolic regulation of antibiotic resistance. His research focuses on the elucidation of the metabolic features antibiotic-resistant bacteria He proposed that antibiotic-resistant bacteria have their metabolomes, naming antibiotic-resistance metabolome (ARM). The crucial biomarkers identified from ARM could reverts the ARM to antibiotic-sensitive metabolome (ASM), which increase the killing efficacy of antibiotics to multidrug-resistant bacteria, biofilm-forming bacteria and persisters (Peng et al, Cell metabolism, 2015). This strategy is also applicable to enhance host immune response to infections through metabolic regulations. Thus, this approach provides a novel strategy to fight against antibiotic-resistant bacteria in a greener but efficient way.

Professor Dr. Luisa Maria Arvide Cambra, Spanish is now Professor with Chair at the University of Almería (Spain) and she was Assistant Professor and Associate Professor at the University of Granada from 1979 on. Thirty nine years of the teaching and researching experience. She is the Director of Research Group HUM113-Estudios Filológicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects, as well as a Member of European Scientific Institute (ESI) Team, Athens Institute for Education & Research (ATINER) in Greece, The Academic Genesis Platform (UAGP) in UK&Turkey and Experts of Academic Excellence Research Centre (EAERC) in Jordan; etc.She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific Conferences. She has visited a many universities and academic institutions of Europe, United States and Arab countries in order to teach and research. Among her works, we have the study and the translation to Spanish of some treatises of Kitab al-tasrif´s Al-Zahrawi, Ibn Qutayba´s texts, Maqamas of Al-Hariri, The Sicilian Questions of Ibn Sab´in, etcetera.

Dr. Subrahmanyam Vangala is currently Founder and Chief Executive Officer at ReaGene Biosciences Private Limited (Bangalore, India). He is an experienced pharma scientist and executive with more than two decades of leadership experience with increasing responsibilities, at global pharma in USA (Wyeth, JNJ, Purdue Pharma and the Shire) and Contract Research Organizations in India (Sai Life and Advinus). He received his Ph.D. Degree in Biochemical Mechanisms of Chemical Carcinogenesis from the Department of Biochemistry, Memorial University of Newfoundland, Canada. He conducted his postdoctoral research in Molecular Toxicology department at University of Colorado at Boulder and continued as a Specialist Scientist (Research Assistant Professor) in Molecular Toxicology at School of Public Health, University of California, Berkeley. Extensive experience in leading DMPK/ADME and Toxicology departments including Clinical Pharmacology, Bioanalytical and Electronic Documentation groups. Managed up to 75 personnel (Research Scientist to Senior Director levels). Built infrastructures from scratch. Supported pharmacokinetics, toxicokinetics, drug metabolism, drug-drug interactions, in-silico modeling, allometric scaling and first-in-human dosing projections, mechanistic pharmacology/toxicology, pharmacogenomics/ toxicogenomics/metabolomics, genetic toxicology, high-resolution mass spectrometry for metabolite identification, pre-formulation development, 3D model development. Prepared short term and long term business plans, budgets, proactively identified road bumps and collaborated extensively with other departments to prepare and execute remedial action plans. He brings with him, unique insights into translational research. He is on the scientific advisory board of Bioagile therapeutics and on the editorial board of journals related to toxicology and analytical research. He has 50 plus peers reviewed publications in peer-reviewed journals including invited book chapters. He has chaired several international symposia in predictive toxicology, idiosyncratic drug toxicity, and DMPK. Served as an editorial board member for international journals. Currently serving as a chief scientific advisor for Bioagile Therapeutics, Trana Labs and Care hospitals. Selected to the expert committee panel for ICMR (Indian Council of Medical Research) on non-animal technologies and prepared a white paper along with other core expert team members. His Current research interests include developing in vitro 3D human models of translational pharmacology and toxicology research for improved clinical translation and use as alternatives to animals in research. Applications of OMICS (Genomics and Metabolomics) with human 3D models to support precision medicine concepts.

Pier Paolo Piccaluga has done MD with honors from Bologna University (1997). He did Specialty in Hematology with honors (2001), PhD in Clinical and Experimental Hematology at Bologna University (2005), Specialty in Pathology with honors at Siena University (2014) and Post-doctoral fellowship at Columbia University, New York (USA). He is a Visiting fellow at Columbia University (USA, 2008) and Kiel University (Germany, 2009), Lecturer in Pathology at Bologna University: 2006-2012. Currently he is appointed as Associate Professor at the Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Medical School, Italy.

Prof: Ashour Saleh Eljamil was born and raised in Tripoli, Libya. He received his Ph.D. in 1988 from the Biochemistry Department, University College Dublin, National University of Ireland, where his interest in lipid biochemistry started. In February 1989 he joined the Department of Biochemistry, Faculty of Medicine, University of Tripoli, Tripoli, Libya, where he is full professor and was head of department from 2005 to 2007. In 1991, he headed the Biochemistry Department at the Medical Laboratory of Salahudeen Hospital in Tripoli. He was director of Medical Laboratory Department and Biochemistry unit at Tripoli Medical Centre from 1996 to 2004. He has presented papers at several scientific meetings in Dublin, Ireland (1986) and was an invited speaker at International Conferences on Drug Discovery and Therapy in Dubai, UAE in 2012, 2013 and 2014, and made presentations on low density lipoprotein-cholesterol, cholesterol and diet ,and serum lipid patterns in type 2 diabetes mellitus. Also plenary speaker, (Effects of Dietary Plant Polyunsaturated Fatty Acids), at The Maghrebian-Finnish Biotechnology Symposium (MFBS 2016). March 19-22, 2016 at Hammamet City, Tunisia and plenary speaker, (Effects of Dietary Plant Polyunsaturated Fatty Acids), at The Maghrebian-Finnish Biotechnology Symposium (MFBS 2018). March 19-22, 2018 at Helsinki, Finland, http://mfbs-2018. He has published papers on the effects of dietary polyunsaturated fatty acids and of pyridoxal-5-phosphate on platelet aggregation and on serum low density lipoprotein cholesterol, in international and regional journals. He has been a frequent visiting professor at Universities in Benghazi, Zawia , Sirte, and Musrata, Libya. He is editorial member of more than international journal. Recently, he published his Lipid Biochemistry for Medical Sciences book by iuniverse in U.S.A

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Jaleel Kareem Ahmed has expertise in evaluation in Iron and steel industry . He registered 3 patents in USA , UK and Iraq about using water in iron industry and wax for storage and transportation of Direct Reduced Iron (DRI) , and using wax for carburizing of steel. Also he used chlorophyll as gamma ray absorber to protect Iraqi children from cancer . He used the mechanically red beet juice as scavenger for poisonous heavy metal ions and anticancer and detoxification of urea and uric acid from human body via urine system . In 2013 he awarded Scientific Medal from Iraqi Government . In 2014 he qualified as a member in Who is Who network. He has been Serving as a reviewer of Journal of Advances in Polymer Technology / Thomson Reuters . He take part in 2016 & 2017 for Quality Star (QS ) World University Ranking Supplement for the QS Intelligence Unit .

Pier Paolo Piccaluga has done MD with honors from Bologna University (1997). He did Specialty in Hematology with honors (2001), PhD in Clinical and Experimental Hematology at Bologna University (2005), Specialty in Pathology with honors at Siena University (2014) and Post-doctoral fellowship at Columbia University, New York (USA). He is a Visiting fellow at Columbia University (USA, 2008) and Kiel University (Germany, 2009), Lecturer in Pathology at Bologna University: 2006-2012. Currently he is appointed as Associate Professor at the Department of Experimental, Diagnostic, and Specialty Medicine, Bologna University Medical School, Italy.

Mishra received his B. S (Honors) and M.S degrees from Patna University ( then nicknamed as Oxford of the East) in India and Ph. D Degree from McMaster University. He received his post –doctoral training with the late Nobel Laureate Professor E. L. Tatum at the Rockefeller University. He was a Fellow for Medical Research of the Jane Coffin Child Fund of the Yale University at the Rockefeller University for two years and then Research Associate with Professor Tatum where he initiated his work in what is now called as Proteomics and Matabolomics.

Chiun Gung Juo obtained his PhD from Department of Chemistry, National Taiwan University in 1997. After graduation, he worked as an analytical team leader at the Everlight Chemical Industrial Corp. and his team analyzed various industrial products and their formulations to help developing new products, such as photo-resin、CDR、DVD dyes、antioxidants and APIs. In 2001, he changed his job to Institute of Biomedical Science, Academia Sinica and established a proteomic core. The core provided the first ICAT analysis service in Taiwan. After that, he went to Molecular Medicine Research Center of Chang Gung University in 2008. There, he set up a metabolomics Core and my own laboratory. His major research interests were developing reliable analytical platforms for the early stage biomarker discovery of cancers then. Now he is senior scientist in PharmaEssentia Corp. Taiwan. He apply his various experience to help developing the protein drug. Besides, he is also one of the council members of Taiwan Society for Mass Spectrometry Since 2003. The major function of the society is to provide the correct knowledge and training of mass spectrometry for the scientists and researchers in Taiwan.

Dr. Joseph Fomusi Ndisang is an Associate Professor in the University of Saskatchewan College of Medicine, Department of Physiology. He received postdoctoral training in Physiology at the University of Saskatchewan College of Medicine from 2000-2005. He obtained a PhD in Pharmacology & Toxicology from the University of Florence, Italy, 2000. He obtained a Doctor of Pharmacy degree from University of Florence, Italy in 1995. He has received several distinguished awards and distinctions including: (i) Fellow of the Canadian Cardiovascular Society (FCCS) in 2016, (ii) Fellow of the American Heart Association (FAHA) in 2011; (iii) Fellow of the International College of Angiology (FICA) in 2007; (iv) Young Investigator Award by International College of Angiology (2007); (v) Young Investigator Award by the American Society of Pharmacology & Experimental Therapeutics-Division for Drug Discovery, Development & Regulatory Affairs (2005); (vi) Young Investigator Award by the Society of Experimental Biology and Medicine (2005); (vii) Caroline tum Suden/Frances A Hellebrandt Professional Opportunity Award for Meritorious Research by the American Physiological Society (2005); and (viii) Recognition Award for Meritorious Research by a Young Investigator by the American Physiological Society (2004). Top 5% of cited authors in journals of Biology and Biochemistry in 2011, by Thomson-Reuters. Currently, Dr. Ndisang is an Editor for Frontiers in Bioscience (impact factor 3.8) and Executive Guest Editor for Current Medicinal Chemistry (impact factor 3.7) He has published more than 64-full length manuscripts in peer-reviewed journals and more than 80 abstracts. Dr. Ndisang has served as external PhD examiner for several universities in Canada, has given more than 30-invited talks, and has also served as peer-reviewer for several reputed journals and granting agencies in United States, United Kingdom, Canada, New Zealand and Poland.

Prof. Hari Misra is currently Head, Molecular Biology Division, Bhabha Atomic Research Centre, Mumbai, India. For last 27 years, Dr Misra has been working on molecular and cellular responses of bacteria to both oxidative stress and DNA damage effects of gamma radiation. He has identified a novel antioxidant / radioprotector, which is found to be a ubiquitous response regulator from one of the most radioresistant bacterium, Deinococcus radiodurans. Catching tail of this molecule, his group discovered a new type of DNA damage response mechanism that seems to be an alternative to the missing classical LexA/RecA type SOS response in this bacterium. Dr. Misra’s current research interests are “Bacterial Genome Biology, Molecular and Cellular responses to oxidative stress and DNA damage, Molecular Genetics and structure-function of proteins, Metabolic engineering and antioxidant / radioprotector / redox biology. Dr Misra has published ~70 research papers in national and international journals of very high repute, with an aggregate IF ~198 and SCI >1000 (Scopus) and >1400 (Goggle scholar). For these contributions, Dr Misra is bestowed with a number of national /international recognitions / awards like “Indian Science Congress- Platinum Jubilee Lecture Award, Homi Bhabha Science and Technology Award, Sarma Memorial Award, DAE Science and Technology Excellence Award, INS Young Scientist Award”. He is elected member of “Guha Research Conference”. Dr Misra is a fellow of National Academy of Sciences, India (FNASc) and Maharashtra Academy of Sciences (FMASc) and Fulbright-Nehru Senior Fellow. Dr Misra has been visiting Scientist/Professor to Harvard Medical School Boston, UTSW-MC Dallas, LSU, Baton Rogue, Zhijiang University China and Korean Atomic Energy Research Institute, Republic of South Korea. He is a Member of BoS and Ph.D. thesis examiner to a number of highly reputed institutions in India. Dr Misra is a member of the American Society of Biochemistry and Molecular Biology (ASBMB), American Society of Microbiologists (ASM), Society of Biological Chemists of India, Association of Microbiologists of India, Environmental Mutagenic Society of India., Indian Society of Cell Biology and Indian Nuclear Society, and has been office bearers of academic societies in India.

Assistant Professor in the Department of Physics, the Graduate Division of Biological and Biomedical Sciences and Emory Antibiotic Resistance Center ,

Dr. Vladimir Tolstikov was awarded PhD degree at the age of 28 years from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is the director of Metabolomics at BERG LLC, USA. He has published more than 60 papers in reputed journals, 5 book chapters and has been serving as an editorial board member of MDPI Metabolites. During his career, he was working in leading research academic institutions and industry including Russian Academy of Medical Sciences, Max Plank Institute, UC Davis, Eli Lilly and Company and others. He is a pioneer in HILIC separations development applied to global Metabolomics. He has participated and contributed to an organization of various international meetings. His current research interests are in the field of AI-guided multi-omics input into the Precision Medicine development.

Preecha P. Yupapin received his B.Ed. in Physics, M.Sc. in Applied Mathematics, PhD in Electrical Engineering from Srinakarinwirote University, Mahidol University and City University of London in 1981, 1983 and 1993 respectively. He was a post-doctor research fellowship in 1994 under the European Community research project. He has been appointed as a visiting professor at Universiti Teknologi Malaysia since 2007. He has been promoted as a Professor of Physics in the Department of Physics, Faculty of Science, King Mongkut’s Institute of Technology Ladkrabang (KMITL), Bangkok, Thailand since 2009. He has authored/co-authored more than 401 published papers in SCOPUS database and 30 chapters and books. He has supervised 70 PhD Students and candidates in both local and international universities. He has also been appointed as an editorial board member and editor in chief of 10 international journals. Professor Yupapin is a member of Thai Institute Physics (TIP), SPIE, OSA senior membership, and was a president of the OSA-Thailand Chapter from 2002-2004.

Prof. Chan obtained his B.Math. (Hons.) in Computer Science and Statistics in 1984 and M.A.Sc. and Ph.D. in Systems Design Engineering in 1985 and 1989 respectively from the University of Waterloo, Waterloo, Ontario, Canada. Soon after graduation, he joined the IBM Canada Laboratory in Toronto, Ontario, Canada as a software analyst and was involved in the development of multimedia and software engineering tools. He joined the Ryerson University as an Associate Professor in 1993 and in 1994, he returned to Hong Kong to join The Hong Kong Polytechnic University where he is currently a Professor in the Department of Computing. Chan’s research interests are in Big Data Analytics, Bioinformatics and Computational Biology, Data Mining, Machine Learning, Evolutionary Computation, Fuzzy Systems, Artificial Intelligence and Software Engineering. He has published 250 research papers in these areas in refereed journals and conference proceedings. He has also served been serving actively as organizer and Program Committee member of numerous conferences in his research areas. Chan’s research has been supported by the Research Grants Council and the Innovation and Technology Commission and the industry. He has been active in “knowledge transfer” through his published work and through consulting and contract research.

Henry M. Sobell completed his studies at Brooklyn Technical High School (1948- 1952), Columbia College (1952-1956), and the University of Virginia School of Medicine (1956-1960). Instead of practicing clinical medicine, he then went to the Massachusetts Institute of Technology (MIT) to join Professor Alexander Rich in the Department of Biology (1960-1965), where, as a Helen Hay Whitney Postdoctoral Fellow, he learned the technique of single crystal X-ray analysis. He then joined the Chemistry Department at the University of Rochester, having been subsequently jointly appointed to both the Chemistry and Molecular Biophysics departments (the latter at the University of Rochester School of Medicine and Dentistry), becoming a full tenured Professor in both departments (1965-1993). He is now retired and living in the Adirondacks in New York, USA.

Dr. Ian James Martins is an Editor/Reveiwer for Open Acess Pub/MDPI journals. Appointed as the Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc). Scientist for Science Advisory Board (USA) and Academic with Academia.edu. H-index of 43, (ResearchGate STATs (23), Mendeley STATS (20). Scientific research citations accumulated to >3300. Lifetime Membership by International Agency for Standards and Ratings as Fellow. Winner (World Academic Championship -2017) in Diabetes and Medical Science (Nutrition). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM.

Athanasios (Sakis) Mantalaris is Professor of BioSystems Engineering in the Department of Chemical Engineering at Imperial College London. He received his PhD (2000) in Chemical Engineering from the University of Rochester. His expertise is in modelling of biological systems and bioprocesses with a focus on mammalian cell culture systems, stem cell bioprocessing, and tissue engineering. He has published over 150 original manuscripts, co-edited one book, and holds several patents with several more pending. He has received several awards including the Junior Moulton Award for best paper by the Institute of Chemical Engineers (IChemE) in 2004. In 2012, he was elected Fellow of the American Institute for Medical & Biological Engineering and in 2013 he was awarded a European Research Council (ERC) Advanced Award.

Professor Dr. Luisa Maria Arvide Cambra, Spanish is now Professor with Chair at the University of Almería (Spain). She also taught at the University of Granada, Spain. Thirty four years of teaching and researching experience. She is Director of Research Group HUM113-Estudios Filológicos from Program of Research of Andalusian Government, where she has managed and directed several academic and scientific contracts and research projects.She is author of a many works on several aspects of the Arabic science and literature in the Middle Ages, as well as Arabic language and linguistics. She has also participated in different prestigious international scientific conferences and visited many Universities and academic institutions in Europe, United States and Arab countries to teach and research.

Assoc Prof Dr Subha Bhassu is currently an academician in Institute of Biological Sciences and has 14 years of experience in teaching in various programs and has develop many course structures that are aligned to the Malaysian MQF programmes for University Malaya (2008-2015) and Inti University College (2000 -2004) and also serve as moderator for Biotechnology courses for INTI University College ( 2008-2015) She is also an Head of Section of Aquatic Molecular Biology and Biotechnology of CEBAR( 2014-current) and associate member of IOES and MRC research centers within University Malaya (2014- current). She is also serves as committee member for International Biosafety Committee Member (IBC) of University Malaya and also auditor for Enforcement committee for Biosafety at the Ministry of Environment and Natural Resources ( 2014-current).

Toshio Suda is an MD from Yokohama City University School of Medicine. He was Professor of the Department of Cell Differentiation at Kumamoto University School of Medicine, now he is Professor of Developmental Biology at Keio University. Toshio Suda and others identified the niche for hematopoietic stem cells and subsequently established the new field of oxidative stress and stem cell aging. The interaction of stem cells and niche is one of hot topics for the stem cell and cancer biology.

Vladimir Tolstikov, Ph.D., is Director of Metabolomics at BERG. He received B.S. and M.S in Organic Chemistry in 1977 from M.V. Lomonosov Institute of Fine Chemical Technology, in Moscow, Russia. He received Ph.D. in Organic Chemistry in 1983 from the Institute of Chemical Means for Plant Protection, Moscow, Russia. He is a pioneer in HILIC separations development applied to Metabolomics. During his career he was working in leading research institutions in USA, Germany, Hungary and Russian Federation. He has joined Eli Lilly and Company in 2012. He is author contributor and participant of 45 conferences, 5 book chapters, and 54 articles

Houkai Li has completed his PhD at the age of 32 years from Shanghai Jiao Tong University and Postdoctoral studies from University of North Carolina (2011.8-2013.5) and Chinese Academy Sciences (2008.11-2011.3) respectively. He is now a Professor at Center for Traditional Chinese Medicine and Systems Biology in Shanghai University of Traditional Chinese Medicine. He has published over 22 papers in reputed journals.

Ching-Wan Lam obtained his MBChB from The Chinese University of Hong Kong in 1991 and FRCPA in 1997 from The Royal College of Pathologists of Australasia with a double scope of practice in Chemical Pathology and Genetics. He is a Fellow of The Australasian Association of Clinical Biochemists’. He obtained his PhD in 2000 from The Chinese University of Hong Kong. He obtained FRCP(Glas) from The Royal College of Physicians and Surgeons of Glasgow in 2012.
Ching-Wan Lam is a chemical pathologist with 20 years experiences in inherited metabolic disease and has over 160 publications on this subject. His research interests include various aspects of inherited metabolic diseases and genetic testing. For example, he identified the MECP2 gene, the first disease gene for non-syndromic infantile autism. The locus is called AUTSX3 (AUTISM, X-LINKED, SUSCEPTIBILITY TO, 3; MIM ID #300496). This work has been incorporated in the formulation of an international guideline for etiologic diagnosis of autism, i.e, The American College of Medical Genetics 2013 clinical practice guideline.
He identified the SMOOTHENED gene to be the driver gene in sporadic medulloblastomas. This work has provided important leads for development of SMOOTHENED inhibitor Vismodegibs. He also identified a new pharmacogenetic disease in which valproate, a first-line anti-epilepsy drug, can trigger onset of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). This work has lead to a change in clinical practice that valproate is now contraindicated to patients with mitochondrial DNA disease by Food and Drug Administration (FDA),The United States of America
Ching-Wan Lam is The Editor, Clinical Chimica Acta, an official journal of The International Federation of Clinical Chemistry and Laboratory Medicine.

Dr. Alan Prem Kumar, Bsc., Msc., Ph.D. serves as Member of Scientific Advisory Board and Member of Business Development Advisory Board at GenoMed, Inc. Following his postdoctoral years, Dr. Kumar joined the Faculty of Medicine, National University of Singapore as an independent Principal Investigator to continue on his expertise on nuclear receptor and cancer biology. From a commercialization perspective, he co-filed a patent on a new potent PPARgamma ligand for treatment of diabetes and cancer. Dr. Kumar has also successfully set up a Singapore-USA collaboration agreement (covering patent issues as well) for another 16 new derivatives drugs - activators and inhibitors of PPARgamma for treatment of diabetes and cancer, thence to a clinical trial here in Singapore. In addition, he has also set up research collaboration between NUS and his collaborator in the USA to identify new synthetic ligands for HNF4alpha and PPARdelta for translation into the clinic. Over the years, Dr. Kumar and his laboratory have forged several relationships with scientists in cancer research and with cancer advocacy groups in Singapore. Dr. Kumar then made a research focus switch from Microbiology to pursue Postdoctoral training in Cancer Research at Sidney Kimmel Cancer Center, California, USA with Dr. Wanda Reynolds. He was awarded a Postdoctoral Fellowship for his work on the role of nuclear receptors in the transcriptional regulation of human myeloperoxidase, a leukocyte enzyme implicated as causative agent in atherosclerosis and Alzheimer's disease. Dr. Kumar earned his BSc, MSc, and Ph.D. in Molecular Biology from University of North Texas, USA. From his Ph.D. work, he discovered a novel regulatory protein, PyrR for the pyrimidine biosynthetic pathway in Pseudomonas.

Paul M. Yen is Professor at Duke-NUS Graduate Medical School in Singapore and Head of the Laboratory of Hormonal Regulation in the Cardiovascular and Metabolic Disorders Program. He obtained his M.D. from Johns Hopkins, completed his residency in internal medicine at University of Chicago and his endocrinology fellowship at NIH. Prior to Duke-NUS he served on the faculty at Johns Hopkins, Harvard, and as section chief at NIDDK, NIH. He has served on the editorial boards of Endocrinology, Molecular Endocrinology, and Thyroid. His current research interests are hormonal regulation of hepatic autophagy and lipid metabolism in non-alcoholic fatty liver disease as well as epigenetic regulation of metabolic genes by thyroid hormone.

Takao Shimizu graduated from Medical School at the University of Tokyo, and took postgraduate course at Kyoto University and Karolinska Institutet, Stockholm. He was appointed as an Associate Professor of Biochemistry and Nutrition, in 1984, and a full professor of Biochemistry and Molecular Biology in 1991. He served as a Dean of Medical School at the University of Tokyo since 2007, and Vice President of the University since 2011. He is currently a professor of the University of Tokyo (Lipidomics laboratory), and director of National Center for Global Health and Medicine (lipid signaling).

Shazib Pervaiz obtained his medical degree (M.B.B.S.) in 1985 from King Edward Medical College, Lahore, Pakistan, and his Ph.D. in 1992 from Southern Methodist University and Baylor University Medical Center, Dallas, TX. He was a fellow in the department of Pathology and later at the Cancer Center at Harvard Medical School/MGH, Boston, MA from 1992-96. Following a short stint at Millennium Pharmaceuticals Inc., Cambridge, MA, he joined the National University of Singapore, Singapore, where he currently holds a Full Professorship in the department of Physiology, Yong Loo Lin School of Medicine. He has held various leadership positions at the YLL School of Medicine, such as Vice Dean (Research and Graduate Education) and Director, National University Medical Institutes (2003- 06). Dr. Pervaiz also holds a joint professorship at the Duke-NUS Graduate Medical School, Singapore and is a member of the Duke-NUS Cancer and Stem Cell Biology Program. He is also an affiliate member of the National University Cancer Institute, NUHS, Singapore, and is a senior faculty at the NUS Graduate School for Integrative Sciences and Engineering and the Singapore-Massachusetts Institute of Technology (MIT) Alliance. Dr. Pervaiz has also served on the scientific advisory board of Behring Diagnostics, Inc., Westwood, MA (1995-96) and more recently of AutoGenomics Inc., Carlsbad, CA and CellWorks Group Inc., San Jose, CA.

Simona Di Francesco is the Director of Urological, Biomedical and Translational Sciences Department. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 M.D , PhD. People's University Nicolaus Copernicus , Cassino (RM) ,Italy 2014 PhD Degree in Clinical and Experimental Medicine and Surgery (CEMS), School of Advanced Studies , Department of Medicine and Aging, University “G. D’Annunzio” Chieti-Pescara. Doctoral Thesis : Metabolic Alterations and Vascular Damage in Prostate Cancer. 2012 AWARD-PIERRE FABRE-CIFU, Italian Society of Urology. 2012 Project Planning Course , G. D’Annunzio University of Chieti-Pescara, School of Advanced Studies. 2012 Advanced English Course For Special Purposes. G. D’annunzio University. School of Advanced Studies. 2012 Course Of Scientific English "Writing Across Science”, G. D’annunzio University, School of Advanced Studies, Nazareth College. 2011 Course Scientific English - Uda-Learning , G. D’Annunzio University of Chieti-Pescara. 2010 Specialization in Urology, G. D’Annunzio University of Chieti-Pescara, with maximum marks cum laude. 2009 Specialization in Internist Echography, G. D’Annunzio University of Chieti-Pescara. 2004 Urostage: Kidney , Prostate, Urinary Bladder. University “G. D’Annunzio” Chieti-Pescara, Department of Medicine and Aging, Section of Urology. 2001 XIV International Course of Digestive and Endocrine Surgery. University “G. D’Annunzio” Chieti-Pescara, School of Medicine and Surgery, Italy. 2001-2002 M.D, G.D’Annunzio University of Chieti-Pescara, Medicine and Surgery.